Eikon Therapeutics, Inc. (EIKN)

Eikon Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Selling, General & Admin	-	55.81	58.48
Research & Development	-	204.54	207.26
Operating Expenses	-	260.34	265.74
Operating Income	-323.55	-260.34	-265.74
Interest Expense (Income)	-14.06	-16.53	-23.7
Other Expense (Income)	0.02	0	-0.04
Pretax Income	-318.91	-243.81	-242
Net Income	-309.52	-243.81	-242
Free Cash Flow	-256.73	-219.6	-219.36
EBITDA	-304.4	-244.41	-269.06
Depreciation & Amortization	19.18	15.94	-3.37
EBIT	-323.57	-260.35	-265.7

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).